Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Transactivating function of integrated hepatitis B virus

S Yamamoto1, E Mita, H Nakatake

  • 1Institute for Molecular and Cellular Biology, Osaka University, Suita, Japan.

Biochemical and Biophysical Research Communications
|December 30, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1.

Journal of viral hepatitis·2014
Same author

Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin.

Journal of viral hepatitis·2014
Same author

Education and Imaging. Gastrointestinal: Unusual duodenal follicular lymphoma observed by magnifying endoscopy with narrow-band imaging.

Journal of gastroenterology and hepatology·2013
Same author

Human immunodeficiency virus (HIV)-associated duodenal lymphoma.

Endoscopy·2012
Same author

Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses.

Journal of viral hepatitis·2009
Same author

Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin.

Journal of viral hepatitis·2009

Integrated Hepatitis B virus (HBV) DNA in liver cancer (HCC) can activate cellular genes. This study found that some HBV DNA integrations exhibit transactivation functions, potentially contributing to hepatocarcinogenesis.

Area of Science:

  • Hepatology
  • Virology
  • Molecular Biology

Background:

  • Hepatocellular carcinoma (HCC) is frequently associated with integrated Hepatitis B virus (HBV) DNA.
  • A specific region of the HBV genome is known to possess transactivation functions.

Purpose of the Study:

  • To investigate whether integrated HBV DNA sequences, including flanking cellular DNA, exhibit transactivation functions.
  • To determine the distribution and potential role of these transactivating effects in hepatocarcinogenesis.

Main Methods:

  • Analysis of a collection of HBV integrants with flanking cellular sequences.
  • Transient cotransfection assays using the HepG2 cell line.
  • Monitoring the expression of cellular genes, such as c-fos, following transfection.

Related Experiment Videos

Main Results:

  • Six out of twelve tested HBV integrants demonstrated transactivation effects.
  • These effects were observed on the expression of cellular genes, including c-fos.
  • Transactivating effects of integrated HBV DNA were found to be widely distributed.

Conclusions:

  • Integrated HBV DNA possesses widely distributed transactivating functions.
  • These functions may play a role in the development of hepatocellular carcinoma.
  • Further investigation into the correlation between HBV DNA integration and hepatocarcinogenesis is warranted.